Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFevertree Regulatory News (FEVR)

Share Price Information for Fevertree (FEVR)

Share Price is delayed by 15 minutes
Get Live Data
807.50    48.50 (6.39%)
Bid:
807.50
Ask:
810.00
Spread: 2.50 (0.31%)
Market Cap: £920.07m
FEVR Live PriceLast checked at - London Stock Exchange

Intraday Fevertree Share Chart

AGM Trading Statement

Today 07:00

RNS Number : 4672H
Fevertree Drinks PLC
09 June 2026
 

Fever-Tree Drinks plc

AGM Statement

 

Fever-Tree Drinks plc (the "Group"), the world's leading supplier of premium carbonated mixers, today announces a trading update ahead of its Annual General Meeting ("AGM"), which is being held today at 11am BST.

 

The Group has made a solid start to the year and remains confident of achieving full-year market expectations. Furthermore, as a reflection of the Board's confidence in the Group's prospects, we are announcing today a further £30m extension to the on-going share buyback programme.

 

During the early part of the year, the Group continued to execute against its strategic priorities, including:

 

· Establishing the platform to accelerate growth in the US

The partnership with Molson Coors has continued to progress well, moving beyond the initial transition period and beginning to leverage the new network, with new account wins, increasing distribution and momentum as we progress through the year.

The brand launched its first national US marketing campaign in April, encompassing TV, digital, e-commerce, and a nationwide sampling initiative.

· Diversification strategy continues to gain scale

A new UK marketing campaign, "Straight Up or Mixed, it's a matter of taste", launched in April, highlighting Fever-Tree's relevance as both a mixer and premium soft drink across a wider range of drinking occasions.

Continued strong momentum in Australia, driven by our premium soft drinks' portfolio, including the launch of Lemon, Lime & Bitters in collaboration with Angostura Bitters.

· Continued category leadership

Further share gains across key markets including the UK, Europe and the US.

· Building business resilience

As disclosed in the FY25 results presentation, 2026 glass costs are fully hedged with respect to the impact of elevated energy costs. Since then, we have significantly extended coverage through 2027 and into 2028 for energy and increased our hedging position across all other significant cost components into 2027.

 

Share Buyback

Today the Board has announced a further £30m extension of the share buyback programme. This builds on the £100m share buyback completed in FY25 and the ongoing £30m tranche, of which £18.9m has been returned as of 5 June 2026.

With confidence in the company's prospects and a cash compounding business model, the Board views a share buyback programme as a highly effective mechanism to drive shareholder value, alongside a progressive dividend policy, while enabling the business to continue to invest to accelerate growth.

Tim Warrillow, CEO of Fever-Tree commented:

"We have continued to make good progress against our strategic priorities so far this year. Fever-Tree is well placed to drive long-term growth across our markets as both a premium mixer and soft drink brand and this year we are significantly increasing marketing investment and innovating to support our growth ambitions. Notwithstanding the current uncertainty in the geopolitical backdrop, we are well hedged from a cost perspective and remain confident in achieving market expectations for both adjusted revenue and EBITDA."

Next Scheduled Announcement

The Group will announce its Interim Results on 10 September 2026.

 

For more information please contact:

Investor queries

Steve Nightingale, Investor Relations Director (Interim) steve.nightingale@fever-tree.com I +44 (0) 7951 849 564

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0) 770 332 9024

 

Nominated Advisor and Broker - Investec Bank plc

David Flin +44 (0)20 7597 5970 | James Hopton +44 (0) 20 7597 2046

Corporate Broker - Jefferies International Limited

Ed Matthews +44 (0) 20 7029 8000

Financial PR advisers - FGS Global

Faeth Birch +44 (0)7768 943 171; Anjali Unnikrishnan +44 (0) 7826 534 233

 

 

Notes to the Editors:

Fever-Tree is the world's leading supplier of premium carbonated mixers by retail sales value, with distribution to over 95 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade").

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMUWONRNOUNRAR
Date   Source Headline
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 20257:00 amRNSTotal Voting Rights
31st Oct 20257:00 amRNSTransaction in Own Shares
30th Oct 20257:00 amRNSTransaction in Own Shares
29th Oct 20257:00 amRNSTransaction in Own Shares
28th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
23rd Oct 20257:00 amRNSTransaction in Own Shares
22nd Oct 20257:00 amRNSTransaction in Own Shares
21st Oct 20257:00 amRNSTransaction in Own Shares
20th Oct 20253:35 pmRNSDirector/PDMR Shareholding
17th Oct 20251:19 pmRNSResults of General Meeting
16th Oct 20257:00 amRNSTransaction in Own Shares
15th Oct 20257:00 amRNSTransaction in Own Shares
14th Oct 20257:00 amRNSTransaction in Own Shares
13th Oct 20257:00 amRNSTransaction in Own Shares
10th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSTransaction in Own Shares
8th Oct 20257:00 amRNSTransaction in Own Shares
7th Oct 20254:25 pmRNSHolding(s) in Company
7th Oct 20257:00 amRNSTransaction in Own Shares
6th Oct 20257:00 amRNSTransaction in Own Shares
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20253:06 pmRNSTR-1: Notification of major holdings
1st Oct 20258:27 amRNSTotal Voting Rights
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20259:39 amRNSHolding(s) in Company
23rd Sep 20257:00 amRNSTransaction in Own Shares
22nd Sep 20257:00 amRNSTransaction in Own Shares
19th Sep 20257:00 amRNSTransaction in Own Shares
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 202512:03 pmRNSDirector/PDMR Shareholding
11th Sep 20258:00 amRNSProposed Share Premium Cancellation
11th Sep 20257:00 amRNSFY25 Interim Results to 30 June 2025
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20255:08 pmRNSHolding(s) in Company
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.